Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5492-5507
DOI: 10.1111/dom.70779 ↗At a glance
Systematische Übersicht in Diabetes, Obesity and Metabolism, published online on 2026-04-27. Written by Rayanne Santos de Paulo and 3 co-authors. Institution: Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity, Gastric Inhibitory Polypeptide. Cited 8 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (original language)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear. This systematic review summarised evidence from randomised clinical trials investigating dietary strategies and nutritional management in individuals treated with these medications.
Methods
The review followed PRISMA guidelines and was registered in PROSPERO (CRD420251181076). Searches were conducted in PubMed, Embase, Scopus and Web of Science. Eligible studies were randomised clinical trials evaluating adults receiving GLP‐1 or dual GIP/GLP‐1 agonists in conjunction with lifestyle or dietary guidance. Outcomes included gastrointestinal symptoms, muscle and bone health and nutritional adequacy.
Results
Sixteen trials involving 7096 participants were included. GLP‐1 and dual agonists consistently increased gastrointestinal symptoms such as nausea, diarrhoea, constipation and vomiting. These effects were often dose‐related and occurred despite background lifestyle or dietary interventions. Lean mass was generally preserved, with reductions proportional to overall weight loss. No study directly assessed bone health, and none reported clinically relevant nutritional deficiencies. Most trials presented a low risk of bias.
Conclusion
GLP‐1 and dual GIP/GLP‐1 agonists frequently cause gastrointestinal discomfort but tend to preserve lean mass during weight loss when used alongside lifestyle interventions. Although dietary guidance is commonly provided, evidence on optimal nutritional approaches remains limited. Further trials are needed to clarify protein requirements, assess musculoskeletal outcomes and establish evidence‐based dietary recommendations to support combined treatment strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.
ORCID profiles: Rayanne Santos de Paulo, Josefina Bressan
Funding
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Cite
APA
de Paulo, R. S., Bonifácio, D. B., de Carvalho, M. H. L., & Bressan, J. (2026). Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes, Obesity and Metabolism, 28(7), 5492-5507. https://doi.org/10.1111/dom.70779
Vancouver
de Paulo RS, Bonifácio DB, de Carvalho MHL, Bressan J. Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes, Obesity and Metabolism. 2026;28(7):5492-5507. doi:10.1111/dom.70779
BibTeX
@article{dePaulo2026,
author = {de Paulo, Rayanne Santos and Bonifácio, Dandara Baia and de Carvalho, Matheus Henrique Lana and Bressan, Josefina},
title = {Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {5492--5507},
doi = {10.1111/dom.70779}
}
EUVIMED